Invitae Acquires Genosity In $200M Deal, Raises $1.15Bn From Softbank Group
Executive Summary
Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.
Topics
- Therapy Areas
- Cancer
- Subjects
- Financing
- M & A
- Commercial
- Research & Development
- Device Areas
- Diagnostics
- In Vitro Diagnostics
- Industries
- Medical Device
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MT143746
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
MT143746
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.